- 专利标题： Compositions and methods for the identification, assessment, prevention and therapy of human cancers
-
申请号： US12002783申请日： 2007-12-17
-
公开(公告)号： US07871775B2公开(公告)日： 2011-01-18
- 发明人: Edwin Clark , Tallessyn Grenfell-Lee , Karen Lu , Lynn Hartmann , Jeffrey L. Brown , Robert C. Bast, Jr. , Gordon B. Mills
- 申请人： Edwin Clark , Tallessyn Grenfell-Lee , Karen Lu , Lynn Hartmann , Jeffrey L. Brown , Robert C. Bast, Jr. , Gordon B. Mills
- 申请人地址： US MA Cambridge US MN Rochester US TX Austin
- 专利权人： Millennium Pharmaceuticals, Inc,Mayo Foundation for Medical Edication and Research,Board of Regents, The University of Texas System
- 当前专利权人： Millennium Pharmaceuticals, Inc,Mayo Foundation for Medical Edication and Research,Board of Regents, The University of Texas System
- 当前专利权人地址： US MA Cambridge US MN Rochester US TX Austin
- 代理机构： McCarter & English, LLP
- 代理商 Maria Laccotripe Zacharakis; Alexandra Jones
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68
摘要：
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.